文献速递炎症性肠病

布地奈德栓剂治疗急性溃疡性直肠炎有效且安全

Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-04-24

一项前瞻性、双盲、双模拟、多中心随机2期试验纳入337例活动性直肠炎患者,比较2 mg布地奈德栓剂、4 mg布地奈德栓剂、1 g美沙拉秦栓剂及2 mg布地奈德联合1 g美沙拉秦栓剂的疗效。结果显示4 mg布地奈德栓剂与1 g美沙拉秦栓剂在症状缓解时间及缓解率上无显著差异,2 mg布地奈德组疗效显著较低;未观察到安全信号,患者治疗接受度高(67%-85%)。

要点

  • 4 mg布地奈德栓剂缓解症状时间与1 g美沙拉秦栓剂相似(29.8天 vs 29.2天)。
  • 2 mg布地奈德栓剂组症状缓解时间显著长于1 g美沙拉秦组(35.5天 vs 29.2天)。
  • 4 mg布地奈德栓剂可作为美沙拉秦局部治疗直肠炎的替代选择。

核心结论

  • 4 mg布地奈德栓剂治疗活动性直肠炎的疗效和安全性上与1 g美沙拉秦栓剂无显著差异。
  • 布地奈德栓剂为直肠炎局部治疗提供了美沙拉秦之外的替代疗法。

研究设计与样本

  • 前瞻性、双盲、双模拟、多中心随机2期试验,纳入337例活动性直肠炎患者。
  • 患者随机分入2 mg布地奈德栓剂组(n=89)、4 mg布地奈德栓剂组(n=79)、1 g美沙拉秦栓剂组(n=81)或2 mg布地奈德联合1 g美沙拉秦栓剂组(n=88)。
  • 研究于2013年11月至2015年7月在欧洲和俄罗斯的36个研究中心进行。
  • 主要终点为临床症状缓解时间,定义为连续3天直肠出血和排便频率评分均为0的第一天。

主要发现

  • 4 mg布地奈德组平均症状缓解时间为29.8天,联合治疗组为29.3天,与标准1 g美沙拉秦组的29.2天相似,而2 mg布地奈德组显著更长(35.5天)。
  • 深度缓解、临床缓解、内镜缓解及黏膜愈合的患者比例在1 g美沙拉秦组、4 mg布地奈德组和联合治疗组间相似,但2 mg布地奈德组显著较低。
  • 未观察到安全信号,患者治疗接受度高(67%-85%)。

临床怎么用

  • 作者认为,布地奈德栓剂可作为美沙拉秦之外用于直肠炎局部治疗的替代疗法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms. Topical mesalamine, the standard treatment, is not always effective. We conducted a randomized phase 2 trial to determine the efficacy and safety of 2 doses of a budesonide suppository vs mesalamine suppositories vs combined budesonide and mesalamine suppositories for proctitis. METHODS: We performed a prospective, double-blind, double-dummy, multicenter trial in 337 patients with active proctitis to compare the efficacies of 4 different suppository treatments. Patients were randomly assigned to groups given 2 mg budesonide suppositories (2 mg BUS; n = 89 patients), 4 mg BUS (n = 79), 1 g mesalamine suppositories (1 g MES; n = 81), or the combination of 2 mg BUS and 1 g MES (n = 88). The study was performed from November 2013 through July 2015 at 36 study sites in Europe and Russia. The primary end point was the time to resolution of clinical symptoms, defined as the first of 3 consecutive days with a score of 0 for rectal bleeding and stool frequency. RESULTS: The mean time to resolution of symptoms in the 4 mg BUS (29.8 days) and combination of 2 mg BUS and 1 g MES (29.3 days) groups resembled that of the standard 1 g MES treatment (29.2 days), but was significantly longer in the 2 mg BUS group (35.5 days). Furthermore, proportions of patients with deep, clinical, and endoscopic remission, as well as mucosal healing, were similar among the 1 g MES, 4 mg BUS, and combination therapy groups, but significantly lower in the group that received 2 mg BUS. No safety signals were observed, and the patients' treatment acceptance was high (67%-85% of patients). CONCLUSIONS: In a multicenter randomized trial, we found that the efficacy and safety of 4 mg BUS in treatment of active proctitis did not differ significantly from those of 1 g MES. Budesonide suppositories offer an alternative therapy to mesalamine for topical treatment of proctitis. Clinicaltrialsregister.eu no: 2012-003362-41.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kruis W, Neshta V, Pesegova M, et al. Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis. Clin Gastroenterol Hepatol. 2018. PMID: 29702300. doi:10.1016/j.cgh.2018.04.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。